文献速递临床试验与 GCP真实世界研究与卫生经济

症状监测与反馈试验(SWIFT):基于登记系统的血液透析整群随机对照试验方案

The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis.
PubMed 文献 · Trials · 2022-05-19

SWIFT是一项基于澳大利亚和新西兰透析与移植登记系统的整群随机对照试验,旨在评估每3个月使用IPOS-Renal量表进行症状监测并向患者及临床团队反馈,与常规照护相比,能否在12个月时改善血液透析患者的健康相关生活质量。试验计划招募143个卫星血液透析中心(至多2400名参与者),主要结局为EQ-5D-5L测量的生活质量变化,并评估总体生存、症状严重程度、医疗资源利用和成本效果。

要点

  • SWIFT在澳大利亚血液透析人群中首次评估定期症状监测与反馈对生活质量的影响。
  • 干预为每3个月使用IPOS-Renal量表进行症状监测并向患者和临床医生反馈。
  • 主要结局为12个月时EQ-5D-5L测量的健康相关生活质量变化。

核心结论

  • SWIFT将检验定期症状监测并向血液透析患者及治疗团队反馈可改善生活质量的假设。
  • SWIFT将为首个严格评估血液透析单位常规收集和报告患者报告结局测量(PROMs)的疗效与成本效果提供信息。

研究设计与样本

  • 基于澳大利亚和新西兰透析与移植(ANZDATA)登记系统的整群随机对照试验。
  • 在接受血液透析的成人中比较每3个月使用IPOS-Renal调查进行症状监测并给予临床医生反馈与常规照护。
  • 计划招募143个卫星血液透析中心,至多2400名参与者。
  • 参与者使用平板电脑完成症状评分,评分提供给参与者和临床医生。

主要发现

  • 主要结局为12个月时EuroQol五维五水平(EQ-5D-5L)工具测量的健康相关生活质量变化。
  • 次要结局包括总体生存、症状严重程度(包括血液透析相关疲劳)、医疗资源利用和成本效果。

临床怎么用

  • SWIFT将为其后临床质量登记系统中患者报告结局测量(PROMs)的收集、存储和报告提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney failure prevalence is increasing worldwide. Haemodialysis, peritoneal dialysis or kidney transplantation are undertaken to extend life with kidney failure. People receiving haemodialysis commonly experience fatigue, pain, nausea, cramping, itching, sleeping difficulties, anxiety and depression. This symptom burden contributes to poor health-related quality of life (QOL) and is a major reason for treatment withdrawal and death. The Symptom monitoring WIth Feedback Trial (SWIFT) will test the hypothesis that regular symptom monitoring with feedback to people receiving haemodialysis and their treating clinical team can improve QOL. METHODS: We are conducting an Australia and New Zealand Dialysis and Transplant (ANZDATA) registry-based cluster randomised controlled trial to determine the clinical- and cost-effectiveness at 12 months, of 3-monthly symptom monitoring using the Integrated Palliative Outcome Scale-Renal (IPOS-Renal) survey with clinician feedback, compared with usual care among adults treated with haemodialysis. Participants complete symptom scoring using a tablet, which are provided to participants and to clinicians. The trial aims to recruit 143 satellite haemodialysis centres, (up to 2400 participants). The primary outcome is change in health-related QOL, as measured by EuroQol 5-Dimension, 5-Level (EQ-5D-5L) instrument. Secondary outcomes include overall survival, symptom severity (including haemodialysis-associated fatigue), healthcare utilisation and cost-effectiveness. DISCUSSION: SWIFT is the first registry-based trial in the Australian haemodialysis population to investigate whether regular symptom monitoring with feedback to participants and clinicians improves QOL. SWIFT is embedded in the ANZDATA Registry facilitating pragmatic recruitment from public and private dialysis clinics, throughout Australia. SWIFT will inform future collection, storage and reporting of patient-reported outcome measures (PROMs) within a clinical quality registry. As the first trial to rigorously estimate the efficacy and cost-effectiveness of routine PROMs collection and reporting in haemodialysis units, SWIFT will provide invaluable information to health services, clinicians and researchers working to improve the lives of those with kidney failure. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12620001061921 . Registered on 16 October 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Greenham L, Bennett PN, Dansie K, et al. The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis. Trials. 2022. PMID: 35590395. doi:10.1186/s13063-022-06355-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。